Researchers used a computational model to compare two types of brain stimulation for Alzheimer's disease. The simulation involved 200 cases with brain activity patterns drawn from a realistic clinical distribution. One group received fixed 40 Hz stimulation, while the other received individualized frequency stimulation based on their specific brain rhythms. The results showed that the personalized approach produced a mean phase-locking value of 0.504 compared to 0.119 for the fixed method. This represents a four-fold advantage for the individualized method. The study also found this advantage held up even when noise levels changed in the model. No safety data were reported because this was a computer simulation rather than a human trial. Readers should note that these findings come from a simulated population and do not prove the treatment works in people. The main takeaway is that this model provides quantitative support for designing future clinical trials that measure individual brain frequencies before treatment. This computational work helps plan next-generation studies but does not yet change current patient care.
Computational model shows individualized gamma stimulation outperforms fixed frequency in Alzheimer's simulationComputational model suggests personalized stimulation beats fixed frequency for Alzheimer's
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a computational model study that simulated a population of 200 individuals with Alzheimer's disease to compare individualized gamma frequency stimulation against a fixed 40 Hz stimulation protocol. The primary outcome was the phase-locking value (PLV), a measure of neural synchronization.
The authors found that individualized frequency stimulation yielded a mean PLV of 0.504 +/- 0.009, compared to 0.119 +/- 0.081 for fixed 40 Hz stimulation. This resulted in a 4.2-fold advantage with a Cohen's d effect size of 4.76 (p < 0.001). In a subgroup with an intrinsic gamma frequency below 36 Hz, the fold advantage was 5.3. A sensitivity analysis showed the fold advantage was robust, ranging from 3.8- to 4.0-fold across different levels of stochastic noise (p < 0.001 at all levels).
The authors acknowledge a key limitation: the study population was simulated. The practice relevance noted is that these results provide quantitative computational support for personalized GENUS protocols and could inform the design of next-generation clinical trials.
The findings are limited to a computational model and cannot be interpreted as clinical efficacy in humans. No causal inference between stimulation and cognitive outcomes is possible from this study.